Healthcare Veteran Stephen L. Newman, M.D., Joins Zavante Therapeutics’ Board of Directors

9/6/2016

SAN DIEGO, CA – September 6, 2016 – Zavante Therapeutics, Inc., a privately-held, late clinical-stage biopharmaceutical company, today announced the appointment of Stephen L. Newman, M.D., to its board of directors.

“We are pleased to add Dr. Newman to our board of directors,” said Ted Schroeder, chief executive officer of Zavante. “His executive level hospital system experience and medical background are an excellent fit for Zavante as we continue the development of ZTI-01, a first in class I.V. antibiotic for use in the hospital setting.”

“Zavante is well positioned within the emerging paradigm in antibiotic drug development  to combat multi-drug resistant pathogens ,” stated Dr. Newman. “I am excited to become involved in this late clinical-stage development company as it continues its efforts to develop a first-in-class I.V. antibiotic.”

Dr. Newman currently serves as Chairman of the Board of CentraForce, LLC, a privately-held healthcare data analytics company. He also serves as Chairman of the JDRF Research Committee and recently completed a term as Vice Chairman of the International Board of Directors of JDRF. Dr. Newman recently completed a five-year term as a member of the Labor, Education and Healthcare Council of the Federal Reserve Bank of Atlanta, and also served as a member of the Boards of Directors of Optimer Pharmaceuticals, Inc., Cadence Pharmaceuticals, Inc. and Hansen Medical, Inc. Dr. Newman retired as Vice Chairman from Tenet Healthcare Corporation in June 2012. Previously, he held executive positions at Columbia/HCA, Inc., and served as Senior Vice President and Chief Medical Officer of Touro Infirmary in New Orleans. Dr. Newman was an Associate Professor of Pediatrics and Medicine at Wright State University School of Medicine, and Director of Gastroenterology and Nutrition Support at Children’s Medical Center in Dayton, Ohio. He holds a bachelor’s degree from Rutgers University, an M.B.A. from Tulane University, and a medical degree from the University of Tennessee. Dr. Newman also completed the Advanced Management Program at the University of Pennsylvania’s Wharton School of Business.

About Zavante Therapeutics, Inc.

Zavante Therapeutics, Inc. is a privately-held, late clinical-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients. The company’s lead product candidate, ZTI-01, is a first-in-class injectable antibiotic with a broad spectrum of bactericidal Gram-negative and Gram-positive activity in vitro, including activity against most contemporary multi-drug resistant strains where current therapeutic choices are severely limited.

Additional information is available at www.zavante.com.

Investor Contact:
Kevin Finney
Zavante Therapeutics
kfinney@zavante.com
@zavantetx

Media Contact:
Amy Caterina
Zavante Therapeutics
acaterina@zavante.com
619-379-0054